Hangzhou Yuanyuan Pharmaceutical

Hangzhou Yuanyuan Pharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on leveraging advanced drug discovery platforms, particularly targeted protein degradation (TPD) and molecular glue technologies, to address previously undruggable targets. Its primary therapeutic areas of interest include oncology and autoimmune diseases, where there is a significant unmet medical need. The lead program, YY001, is an orally bioavailable small molecule currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Yuanyuan Pharmaceutical's R&D strategy combines deep biological insights with sophisticated medicinal chemistry to optimize the pharmacological profiles of its candidates. Supported by prominent venture capital firms, the company continues to expand its pipeline with several preclinical programs aimed at novel mechanisms of action.